| 27th Feb 2020 7:00 am |
GNW |
Verona Pharma Reports Financial Results for the Full Year Ended December 31, 2019 and Provides Corporate Update |
| 21st Feb 2020 7:00 am |
GNW |
Verona Pharma plc to Announce Financial Results for Full Year Ended December 31, 2019 and Provide Corporate Update |
| 14th Feb 2020 7:00 am |
GNW |
Verona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research |
| 7th Feb 2020 7:00 am |
GNW |
Holding(s) in Company TR-1: Standard form for notification of major holdings |
| 3rd Feb 2020 7:00 am |
GNW |
Verona Pharma Announces Senior Management Changes |
| 28th Jan 2020 7:00 am |
GNW |
Verona Pharma to Present at LSX World Congress 2020 |
| 17th Jan 2020 1:06 pm |
GNW |
Holding(s) in Company TR-1: Standard form for notification of major holdings |
| 13th Jan 2020 4:41 pm |
RNS |
Second Price Monitoring Extn |
| 13th Jan 2020 4:35 pm |
RNS |
Price Monitoring Extension |
| 13th Jan 2020 5:00 am |
GNW |
Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy |
| 10th Jan 2020 11:00 pm |
GNW |
Verona Pharma to Report 4 Week Phase 2b COPD Dose-ranging Study Results with Nebulized Ensifentrine on Top of Tiotropium Therapy |
| 7th Jan 2020 7:00 am |
GNW |
Verona Pharma Appoints David Moskowitz as Vice President, Capital Markets Strategy & Investor Relations |
| 28th Nov 2019 10:25 am |
GNW |
Holding(s) in Company TR-1: Standard form for notification of major holdings |
| 27th Nov 2019 7:00 am |
GNW |
Verona Pharma plc: Grant of Options to PDMR |
| 18th Nov 2019 7:00 am |
GNW |
Verona Pharma plc: PDMR Dealing – Purchase by Chairman |
| 14th Nov 2019 7:00 am |
GNW |
Verona Pharma plc: PDMR Dealing – Purchase by Chairman |
| 13th Nov 2019 7:00 am |
GNW |
Verona Pharma to Present at Jefferies 2019 London Healthcare Conference |
| 11th Nov 2019 7:00 am |
GNW |
Verona Pharma to Participate in Two Upcoming Institutional Investor Conferences in New York |
| 5th Nov 2019 7:00 am |
GNW |
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2019 |
| 29th Oct 2019 7:00 am |
GNW |
Verona Pharma to Announce Financial Results for the Three and Nine Months Ended September 30, 2019 and Provide Clinical Development Update |
| 17th Oct 2019 7:00 am |
GNW |
Verona Pharma Completes Enrollment in Phase 2b Clinical Trial with Nebulized Ensifentrine in moderate-to-severe COPD |
| 15th Oct 2019 7:00 am |
GNW |
Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019 |
| 19th Sep 2019 7:00 am |
GNW |
Verona Pharma to Present Phase 2 Data with Ensifentrine Dry Powder Inhaler Formulation in COPD at European Respiratory Society International Congress 2019 |
| 9th Sep 2019 2:33 pm |
GNW |
Holding(s) in Company TR-1: Standard form for notification of major holdings |
| 3rd Sep 2019 7:00 am |
GNW |
Verona Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference |
| 9th Aug 2019 9:35 am |
GNW |
Verona Pharma plc: PDMR Dealing |
| 6th Aug 2019 7:00 am |
GNW |
Verona Pharma plc: Operational Update and Financial Results for the Three and Six Months Ended June 30, 2019 |
| 5th Aug 2019 7:00 am |
GNW |
Verona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPD |
| 30th Jul 2019 7:00 am |
GNW |
Verona Pharma to Announce Financial Results for Second Quarter Ended June 30, 2019 and Provide Clinical Development Update |
| 24th Jul 2019 7:00 am |
GNW |
Verona Pharma to Attend BTIG Biotechnology Conference 2019 and Present at 2019 Wedbush PacGrow Healthcare Conference |
| 25th Jun 2019 7:00 am |
GNW |
Verona Pharma Strengthens its Clinical Team Ahead of Phase 3 Development of Ensifentrine |
| 4th Jun 2019 7:00 am |
GNW |
Verona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPD |
| 30th May 2019 7:00 am |
GNW |
Verona Pharma to Present at Jefferies 2019 Global Healthcare Conference |
| 29th May 2019 11:07 am |
RNS |
PDMR Dealing |
| 20th May 2019 3:15 pm |
GNW |
Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at American Thoracic Society 2019 International Conference |
| 7th May 2019 12:51 pm |
GNW |
Result of AGM |
| 7th May 2019 7:00 am |
GNW |
Verona Pharma plc Operational Update and Financial Results for the Three Months Ended March 31, 2019 |
| 7th May 2019 7:00 am |
GNW |
Verona Pharma Initiates Additional Phase 2b Clinical Trial with Nebulized Ensifentrine to Inform Dose Selection for Phase 3 Trials |
| 2nd May 2019 12:00 pm |
GNW |
Verona Pharma to Present Clinical Trial Data of Ensifentrine for COPD Maintenance Treatment at American Thoracic Society 2019 International Conference |
| 1st May 2019 7:00 am |
GNW |
Verona Pharma to Announce Financial Results for First Quarter Ended March 31, 2019 and Provide Clinical Development Update |
